OraVerse® is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where local anesthetic containing a vasoconstrictor was used. In clinical trials, the patients were able to regain normal sensation twice as fast vs. the control group.
These studies showed that on average people who are given OraVerse® not only return to normal sensation twice as fast, but they can smile, speak, and drink normally sooner, and drooling is minimized.
OraVerse® is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor.
OraVerse® is not recommended for use in children less than 6 years of age or weighing less than 33 lbs.
The most common adverse event with OraVerse® greater than the control group was injection site pain (5% vs. 4%).
OraVerse® is administered by your dental professional in the same way the local anesthetic was given so that you can return to normal sensation and function faster.
If you’d like to have OraVerse® as part of your next visit, just ask our office for more details.
Important Safety Information
In clinical trials, the most common adverse events with OraVerse® (phentolamine mesylate) were post procedural pain, injection site pain, increased or decreased heart rate and headache. Following injections of phentolamine in non-dental procedures, substantial decreases in blood pressure have occurred which resulted in heart attacks as well as spasms and blocked blood vessels in the brain. Although such effects are uncommon with OraVerse®, you should alert your doctor if you experience an increase in heart rate or abnormal heart rhythm (palpitations), particularly if you have a history of heart disease.